Platform Disclaimer
Effective Date: January 1, 2026 • Last Updated: April 21, 2026
Bridge BioHealth Consulting LLC provides these disclaimers to clearly define the scope and limitations of our AI tools, services, and platform. Please read them carefully before using our platform.
Important: Read Before Using Our Platform
Bridge BioHealth's AI tools and platform services are for strategic decision-support and educational purposes only. They do not constitute regulatory advice, legal counsel, financial advice, investment recommendations, medical advice, or a fairness opinion. Always consult qualified professionals before making material decisions. Bridge BioHealth Consulting LLC is not a registered investment advisor, broker-dealer, law firm, or FDA-approved consulting firm.
AI Tools — Not Professional Advice
All AI-generated reports, analyses, roadmaps, scores, and recommendations produced by Bridge BioHealth's platform tools (including the FDA Pathway Generator, Go/No-Go Decision Engine, M&A Pre-Acquisition Check, AI Lead Evaluation, and Grant Readiness Score) are provided for strategic decision-support and educational purposes ONLY. These outputs do NOT constitute professional regulatory advice, legal counsel, financial advice, investment recommendations, medical advice, or a fairness opinion. Bridge BioHealth Consulting LLC is not a registered investment advisor, broker-dealer, law firm, medical practice, or federally-recognized regulatory consulting firm. All AI outputs should be independently verified by qualified legal, financial, scientific, and regulatory professionals before any decision is made.
FDA Regulatory Intelligence — Not FDA Guidance
The FDA Pathway Generator and related regulatory tools produce AI-generated pathway recommendations based on publicly available FDA guidance documents, peer-reviewed literature, and drug development precedents. These outputs are NOT official FDA guidance, pre-submission meeting feedback, or regulatory determinations. The FDA makes all regulatory decisions independently. Drug development programs must engage directly with the FDA through appropriate channels (pre-IND meetings, INTERACT meetings, etc.). Bridge BioHealth's AI regulatory intelligence is designed to help sponsors prepare for such interactions, not substitute for them. Regulatory pathways are program-specific and subject to change — always consult a qualified regulatory affairs professional and the current FDA guidance documents for your specific program.
M&A Due Diligence — Not a Fairness Opinion
The M&A Pre-Acquisition Intelligence Check produces AI-generated deal assessments based on user-submitted information. This tool does NOT constitute a fairness opinion, valuation opinion, independent financial analysis, or investment banking advice. Bridge BioHealth is not a registered investment bank or broker-dealer. M&A decisions involve material legal, financial, regulatory, and operational complexities that require qualified legal counsel, investment bankers, and independent auditors. The deal scores, valuation ranges, and recommendations generated by this tool are algorithmic estimates intended to support — not replace — professional due diligence. Bridge BioHealth makes no representations regarding the accuracy of valuations or deal outcomes. Probability estimates are based on published M&A research and do not predict individual deal outcomes.
Grant Writing — No Funding Guarantee
Bridge BioHealth's grant writing services and AI grant matching tools are intended to improve the quality and competitiveness of grant applications. We do not guarantee funding outcomes. Grant awards are determined by independent peer review panels and agency priorities outside of Bridge BioHealth's control. Historical success rates cited are based on published data and our service track record but are not guarantees of future performance. NIH, NSF, DoD, ERC, and other funders make all award decisions independently.
BioShare Marketplace — Non-Custodial Platform
Bridge BioHealth operates the BioShare Marketplace as a non-custodial connection platform only. We do not take custody of, store, transport, test, evaluate, or handle any biological materials, chemical compounds, datasets, intellectual property, or other resources listed on the Marketplace. We are not a party to any transaction facilitated through the Marketplace. All exchanges, material transfers, licensing agreements, and commercial arrangements occur directly between the listing party and the acquiring party. Buyers and sellers are solely responsible for ensuring compliance with all applicable laws and regulations including biosafety regulations, export controls, material transfer agreements (MTAs), institutional policies, and applicable intellectual property laws. Bridge BioHealth verifies listing eligibility based on stated expiry dates and categories but does not independently verify the quality, safety, or regulatory status of listed materials.
Manuscript Writing — No Publication Guarantee
Bridge BioHealth's Data to Manuscript Program produces professionally written scientific manuscripts. We do not guarantee journal acceptance or publication. Publication decisions are made solely by journal editors and peer reviewers. Bridge BioHealth is credited as a writing support service. All IP ownership remains with the data contributor. We provide assistance in identifying target journals appropriate to the data, but final journal selection and submission are at the discretion of the PI and co-authors. The 90-day turnaround SLA refers to delivery of a completed manuscript draft to the client, not publication.
Go/No-Go Decision Engine — Educational Tool
The Go/No-Go Decision Engine produces evidence-based evaluations of drug programs for educational and strategic planning purposes. The scoring methodology is grounded in published drug attrition research but is NOT a substitute for comprehensive scientific due diligence, regulatory review, or expert scientific assessment. Program scores do not predict regulatory outcomes, clinical success, or investment returns. The algorithm applies statistical averages from published literature — individual program outcomes vary significantly based on factors that cannot be captured in a structured questionnaire. This tool is designed to facilitate more informed internal discussions and should complement, not replace, expert scientific review.
General Information Disclaimer
All content on the Bridge BioHealth platform, including articles, glossary entries, industry statistics, case studies, and blog posts, is provided for general informational purposes only. Industry statistics are sourced from published research and may not reflect current conditions. Bridge BioHealth makes no warranties regarding the accuracy, completeness, or timeliness of any content. External links are provided for reference only — we are not responsible for the content of third-party websites. Bridge BioHealth's views and analyses are our own and do not represent the views of any regulatory agency, academic institution, or professional body.
Non-Custodial Platform Summary
Bridge BioHealth LLC operates exclusively as a connection and analytics platform. We do not: hold, transport, or store biological materials or compounds; provide legal, financial, or medical services; guarantee regulatory approvals, grant awards, or publication acceptance; guarantee investment returns or deal outcomes; act as a counterparty in any Marketplace transaction. © 2026 Bridge BioHealth Consulting LLC. All rights reserved.